Fatty Liver Treatment Market: By Drug; By End-User & By Region - Forecast 2016-2021

  • ID: 3973760
  • Report
  • 139 pages
  • IndustryARC
1 of 3
Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells. The major causes of fatty liver disease are obesity and excessive alcohol consumption. The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. It is expected to be one of the leading causes of hepatocellular carcinoma.

The technological advancements and the routine liver function tests have increased the detection of fatty liver disease in the early stage. The increase in incidence of fatty liver disease associated with excessive alcohol intake is expected to create an opportunity for the treatment market during the forecast period. The market for overall fatty liver treatment is expected to grow significantly owning to the availability of variety of agents for fatty liver treatment. However, the market growth can be restrained owing to the side effects associated with the treatment, coupled with stringent regulatory requirements.

This report identifies the global fatty Liver Treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global fatty Liver Treatment market.

Geographically, North America is estimated to hold the largest share in the fatty liver treatment market. Asia-Pacific is estimated to witness the highest growth during the forecast period in the fatty liver treatment market owing to rising drug and alcohol abuse coupled with increasing incidences of lifestyle related diseases.
This report segments global fatty Liver Treatment market on the basis of drug, end-use, and regional market as follows:
Global Fatty Liver Treatment Market, by Drug: Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
Global Fatty Liver Treatment Market, by End-Use: Hospitals and Clinics
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the global Fatty Liver Treatment market. Some of the major companies’ profiles in detail are as follows:
Cardax, Inc.

Daewoong Co., Ltd.

Hoffmann-La Roche Ltd.

Glenmark
GW Pharmaceuticals
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Global Fatty Liver Treatment Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Global Fatty Liver Treatment Market– Market Forces
4.1. Drivers
4.1.1. Cost Effective Treatment Procedures
4.1.2. Advancement in Technology
4.2. Restraints
4.2.1. Side-Effects
4.3. Opportunities
4.3.1. Increasing Incidence of Alcohol Related Diseases
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Global Fatty Liver Treatment Market, By Drug
5.1. Thiazolidinedione
5.2. Vitamin E
5.3. Metformin
5.4. Statins
5.5. Polyunsaturated fatty acids
5.6. Angiotensin receptor blockers
5.7. Pentoxifylline

6. Global Fatty Liver Treatment Market, By End-Use
6.1. Hospitals
6.2. Clinics

7. Global Fatty Liver Treatment Market, By Geography
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Global Fatty Liver Treatment – Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles
9.1. Cardax, Inc.
9.1.1. Introduction
9.1.2. Financials
9.1.3. Key Insights
9.1.4. Key Strategy
9.1.5. Product Portfolio
9.1.6. SWOT Analysis
9.2. Daewoong Co., Ltd.
9.2.1. Introduction
9.2.2. Financials
9.2.3. Key Insights
9.2.4. Key Strategy
9.2.5. Product Portfolio
9.2.6. SWOT Analysis
9.3. Hoffmann-La Roche Ltd.
9.3.1. Introduction
9.3.2. Financials
9.3.3. Key Insights
9.3.4. Key Strategy
9.3.5. Product Portfolio
9.3.6. SWOT Analysis
9.4. Glenmark
9.4.1. Introduction
9.4.2. Financials
9.4.3. Key Insights
9.4.4. Key Strategy
9.4.5. Product Portfolio
9.4.6. SWOT Analysis
9.5. GW Pharmaceuticals
9.5.1. Introduction
9.5.2. Financials
9.5.3. Key Insights
9.5.4. Key Strategy
9.5.5. Product Portfolio
9.5.6. SWOT Analysis
9.6. Limerick BioPharma, Inc.
9.6.1. Introduction
9.6.2. Financials
9.6.3. Key Insights
9.6.4. Key Strategy
9.6.5. Product Portfolio
9.6.6. SWOT Analysis
9.7. Merck & Co., Inc.
9.7.1. Introduction
9.7.2. Financials
9.7.3. Key Insights
9.7.4. Key Strategy
9.7.5. Product Portfolio
9.7.6. SWOT Analysis
9.8. Novartis AG
9.8.1. Introduction
9.8.2. Financials
9.8.3. Key Insights
9.8.4. Key Strategy
9.8.5. Product Portfolio
9.8.6. SWOT Analysis
9.9. Orchid Chemicals & Pharmaceuticals Ltd
9.9.1. Introduction
9.9.2. Financials
9.9.3. Key Insights
9.9.4. Key Strategy
9.9.5. Product Portfolio
9.9.6. SWOT Analysis
9.10. AstraZeneca
9.10.1. Introduction
9.10.2. Financials
9.10.3. Key Insights
9.10.4. Key Strategy
9.10.5. Product Portfolio
9.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll